Cargando…

Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer

Rationale: Paclitaxel resistance is a major concern when treating triple-negative breast cancer (TNBC) patients. We aimed to identify candidates causing paclitaxel resistance and explore their significance in TNBC therapeutics. Methods: A genome-wide CRISPR screening, integrated with transcriptome a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lian, Bi, Pei, Yu-Chen, Jiang, Yi-Zhou, Xue, Meng-Zhu, Li, Da-Qiang, Li, Xiao-Guang, Zheng, Yi-Zi, Liu, Xi-Yu, Qiao, Feng, Sun, Wei-Li, Ling, Hong, He, Min, Yao, Ling, Hu, Xin, Shao, Zhi-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532680/ https://www.ncbi.nlm.nih.gov/pubmed/33042272 http://dx.doi.org/10.7150/thno.44997

Ejemplares similares

SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer
por: Liu, Xi-Yu, et al.
Publicado: (2020)

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
por: Maccallini, Cristina, et al.
Publicado: (2022)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

TAZ2 truncation confers overactivation of p300 and cellular vulnerability to HDAC inhibition
por: Xu, Longxia, et al.
Publicado: (2023)

Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer
por: Liao, Li, et al.
Publicado: (2023)

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer
por: Li, Mengxing, et al.
Publicado: (2021)

HDAC inhibition potentiates immunotherapy in triple negative breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer
por: Peterlongo, Paolo, et al.
Publicado: (2021)

Genetic evaluation of BRCA1-A complex genes with triple-negative breast cancer susceptibility in Chinese women
por: Ling, Hong, et al.
Publicado: (2016)

Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
por: Wang, Ruo-Xi, et al.
Publicado: (2016)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial
por: Yu, Ke-Da, et al.
Publicado: (2020)

Association of HDAC8 Expression with Pathological Findings in Triple Negative and Non-Triple Negative Breast Cancer: Implications for Diagnosis
por: Menbari, Mohammad-Nazir, et al.
Publicado: (2020)

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
por: Chen, Li, et al.
Publicado: (2022)

Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo
por: Zuco, Valentina, et al.
Publicado: (2011)

Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation
por: Wang, Meng, et al.
Publicado: (2021)

Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer
por: Huang, Yu-Hsiang, et al.
Publicado: (2021)

Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells
por: Sezer, Gülay, et al.
Publicado: (2022)

A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
por: Liu, Yuetong, et al.
Publicado: (2023)

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer
por: Figlioli, Gisella, et al.
Publicado: (2019)

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019)

Self-Assembly Engineering Nanodrugs Composed of Paclitaxel and Curcumin for the Combined Treatment of Triple Negative Breast Cancer
por: Zuo, Shuting, et al.
Publicado: (2021)

Effect of Ect2 Expression on the Growth of Triple-Negative Breast Cancer Cells with Paclitaxel Intervention
por: Wang, Hongkun, et al.
Publicado: (2020)

Integrated analysis reveals the molecular features of fibrosis in triple-negative breast cancer
por: Ding, Jia-Han, et al.
Publicado: (2022)

Knockdown of SERPINE1 reverses resistance of triple-negative breast cancer to paclitaxel via suppression of VEGFA
por: Zhang, Qian, et al.
Publicado: (2020)

Identification of Key Genes Affecting the Tumor Microenvironment and Prognosis of Triple-Negative Breast Cancer
por: Yi, Jiarong, et al.
Publicado: (2021)

Combined in vitro/in vivo genome-wide CRISPR screens in triple negative breast cancer identify cancer stemness regulators in paclitaxel resistance
por: Yan, Gang, et al.
Publicado: (2023)

Bioinformatics analysis of key genes in triple negative breast cancer and validation of oncogene PLK1
por: Ren, Yi, et al.
Publicado: (2020)

Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer
por: Qi, Yanfeng, et al.
Publicado: (2012)

Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
por: Li, Chia-Jung, et al.
Publicado: (2021)

Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers
por: Wang, Lei, et al.
Publicado: (2020)

CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer
por: Han, Xin-le, et al.
Publicado: (2021)

A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer
por: Wu, Xiaoqiu, et al.
Publicado: (2020)

HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer
por: Lin, Ching-Ling, et al.
Publicado: (2019)

Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models
por: Huang, Pengyu, et al.
Publicado: (2016)

Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy
por: Chen, Yi-Fan, et al.
Publicado: (2017)

Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
por: Wang, Chengzheng, et al.
Publicado: (2023)

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer
por: Wu, Si-Yu, et al.
Publicado: (2021)

Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells
por: Sulaiman, Andrew, et al.
Publicado: (2018)

OTUD7B upregulation predicts a poor response to paclitaxel in patients with triple-negative breast cancer
por: Chiu, Hui-Wen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5hugecgj8erul1q5109hemdpck